ClinicalTrials.gg
CompletedNCT06720233Updated Dec 6, 2024

Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis

A Phase 3 interventional study of SAL-0951 tablets in Anemia, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 22 years 9 months after the study started (first participant enrolled Feb 2002, registered Dec 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies in Anemia with a site in China — 33 open to participants now, 42 under way, 8 of them phase 3. Anemia · China.

Enrollment
82nd of 97
37 · median 120
Started
2002
the only one that year
Phase 3
22 of 115
2 open now
Registered
94th of 115
by date
Lead sponsor
5 of 115
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Among the 115 studies in Anemia with a site in China, this one is the 82nd largest by enrollment of the 97 interventional ones that give a count, is the only one that started in 2002, is one of 22 in phase 3, and was the 94th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

33 of the 115 studies in Anemia with a site in China are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Anemia with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of SAL-0951 in Chinese patients receiving peritoneal dialysis with chronic kidney disease and anemia

Read the detailed description

This is a multicenter, open-label, single-arm clinical study (using individualized dose adjustment design). Eligible subjects after screening will be assigned to the test group for a 24-week treatment to verify the efficacy and safety of SAL-0951 in the treatment of renal anemia in patients receiving peritoneal dialysis.

The study is mainly divided into four stages: screening period (2 or 4 weeks before administration), initial treatment period (4 weeks), maintenance treatment period (20 weeks), and safety follow-up period (2 weeks), requiring a total of 11 visits. This study includes the 24th week visit as the end of treatment visit (EOT) and the 26th week as the end of study visit (EOS). Subjects who withdraw early will be required to complete the research procedure for Week 24.

03

Conditions studied

  • Anemia

Keywords

  • Anemia
  • Renal Insufficiency
  • Chronic Dialyses
  • Peritoneal Dialysis
  • Enarodustat
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.Dry weight 45 to 100 kg; 2.Patients receiving continuous peritoneal dialysis for at least 12 weeks prior to the screening visit and no other blood purification treatment (including hemodialysis) within 12 weeks prior to the screening visit; 3.Patients continuing on peritoneal dialysis during the period between the screening visit and the end of study, without receiving other blood purification treatment (including hemodialysis); 4.Patients with TSAT*1 >20% or ferritin*1 >50 μg/L at screening visit;

  • 1: Invalid test values cannot be used to determine a subject's eligibility. If serum iron values are invalid values, TSAT values shall also be handled as invalid values and re-test will be performed (For patients with ferritin >50 μg/L, there is no need for re-test).

    5.Patients who have received ESAs within 8 weeks prior to screening visit should meet the following requirements simultaneously* (* those with use of darbepoetin alfa (DA) prior to screening should meet all of the following 4 criteria, and those with use of rHuEPO prior to screening should meet both criteria #2 and #4):

    1. If the treatment drug is DA prior to the screening visit 1, the most recent treatment before the screening visit should be performed 2 weeks (including 2 weeks) prior to the screening visit 1;
    2. Treatment prescription regimen (including rHuEPO or DA, in which DA needs to be administered on the day of visit 1) consistent with the most recent ESAs prior to screening should be received at the screening visit 1 (same ESAs should be administered at the same dose; if the weekly dose is uneven in the regimen of the most recent ESAs prior to screening, for example, rHuEPO 5000 IU and 3000 IU are injected once every week alternately, proceed the treatment as per original regimen in the screening period; if rHuEPO is originally administered multiple doses weekly and the date of recent dose is less than 3 days from the day of the first dose of study drug, rHuEPO should be discontinued; if rHuEPO is originally administered weekly, the day of rHuEPO administration should be 3 days before the day of the first dose of study drug. Among them, rHuEPO of different brands is regarded as the same kind of ESAs. The acceptable average weekly dose is ≥750 IU and ≤9000 IU in a cycle of treatment based on the last prescription prior to screening, usually 4 weeks.);
    3. If the treatment drug is DA prior to screening visit 1, the acceptable average weekly dose is 10 µg to 30 µg in a cycle of treatment based on the last prescription of DA prior to screening, usually 4 weeks. It is not expected to receive DA from the day after screening visit 1 until the first dose of study drug according to the original dosing regimen, except in exceptional cases*1;
  • 1: The same DA regimen adopted at screening visit 1 will be administered (at the same dose, using same drug) approximately 2 weeks after screening visit 1, provided that the time interval from the most recent DA therapy prior to screening visit 1 to screening visit 1 is less than 3 weeks (≥14 days and \<21 days), and the screening period is 4 weeks.

    4)Patients with levels ≥95 g/L and ≤120 g/L at the screening visit; 6.Patients not treated with ESAs (ESAs-naïve) within 12 weeks prior to the screening visit should meet the following a) and b) requirements:

    1. Patients not treated with ESAs during the period between screening visit 1 and the date of first dose of study drug
    2. Patients with Hb levels ≥80 g/L and ≤105 g/L at the screening visit 7.Voluntary participation in the trial and signature of .

Exclusion criteria

Exclusion Criteria:

  1. Patients with peritoneal dialysis catheter problems (dislocation, etc.), peritonitis, peritoneal dialysis catheter infection, etc. during the period between 4 weeks prior to the screening visit and the first dose of study drug, affecting the continuation of peritoneal dialysis;
  2. Patients with poorly controlled hypertension (e.g., systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg at screening visit);
  3. Patients with severe hepatobiliary disease (e.g., or ALT >2.5 × value at screening visit, hepatic cirrhosis, total ≥1.5 × upper limit of normal value at screening visit);
  4. Patients with congestive heart failure ( [NYHA] Class III or greater) or unstable angina during the period between 24 weeks prior to the screening visit and the first dose of study drug;
  5. Patients who have developed myocardial infarction, , cerebral infarction (excluding asymptomatic cerebral infarction), or venous thromboembolism (pulmonary embolism or deep vein thrombosis) during the period between 24 weeks prior to the screening visit and the first dose of study drug;
  6. Patients who will undergo an ophthalmological procedure (laser photocoagulation therapy or vitreous surgery) for the treatment of diabetic retinopathy, diabetic macular edema, or age-related macular degeneration during the period between screening visit and the end of the study;
  7. Patients who have undergone erythrocyte transfusion during the period between 12 weeks prior to the screening visit and the first dose of study drug (as clinically indicated, transfusions of blood products that do not contain red blood cells may be excluded, such as plasma, albumin, etc.)
  8. Subjects who have received growth hormone, thyroxine, testosterone enanthate, or mepitiostane during the period between 12 weeks prior to the screening visit and the first dose of study drug;
  9. Patients with severe hyperparathyroidism (e.g., intact-parathyroid hormone [intact-PTH] ≥500 pg/mL at screening visit);
  10. Patients with severe infections (such as active pulmonary tuberculosis, fungal infections, etc.), systemic hematological diseases (such as myelodysplastic syndrome, aplastic anemia, abnormal disease, etc.) or hemolytic anemia, or patients with anemia caused by bleeding disorders (such as gastrointestinal bleeding, etc.);
  11. Except for glomerulonephritis, anemia patients suspected to be caused by non-infectious chronic inflammatory diseases such as systemic lupus erythematosus, rheumatoid arthritis, celiac disease, etc.;
  12. Patients with polycystic kidney disease, any previous functional organ transplantation or scheduled organ transplantation;
  13. Patients positive for any of the following: (HIV) antibodies, surface antigen (HBsAg), or anti- virus antibodies (anti-HCV Ab), or confirmed syphilis requiring treatment;
  14. Patients with medical history of (including hematological malignancy), except for tumors determined to be cured or in remission for 5 years, skin basal cell or squamous cell carcinoma that has undergone radical resection, or in situ carcinoma of any part;
  15. Patients with a history of severe drug allergies (such as anaphylactic shock), or allergy to other HIF-PH inhibitors;
  16. History of drug or alcohol abuse in the past two years*;

    *An average of 14 units of alcohol per week (1 unit ≈ 360 mL of beer, or 45 mL of liquor, or 150 mL of wine) in 2 years before screening

  17. Patients who have received another product (or study drug), have received treatment with an investigational device (or study device), or have participated in clinical research involving intervention (medical action beyond the scope of ordinary medical practice intended for research purposes) and received treatment during the period between 12 weeks prior to the screening visit and the first dose of study drug;
  18. Patients who have received treatment with other HIF-PH inhibitors within 8 weeks prior to the screening or have previously participated in a clinical study of SAL-0951 and received the investigational product (active drug);
  19. Patients who are pregnant, lactating, or may be pregnant (the possibility of pregnancy cannot be ruled out by the investigator based on the results of pregnancy test at screening visit);
  20. Women of or men with sexual partners of childbearing potential who do not agree to take effective * from the time of signing the until the end of the dosing study;

    *Effective contraceptive methods include transdermal patches, oral medication, implantable or injectable contraceptives, abstinence or birth control surgery.

  21. Any other medical condition that, in the opinion of the investigator, could pose a safety risk to the subject in this study, could confound efficacy or safety assessment, or could interfere with the subject's participation in the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    SAL-0951 tablets

    initial phase:4mg QD subsequent phase:1mg~8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks

    Drug: SAL-0951 tablets

Interventions

  • initial phase:4mg QD subsequent phase:1mg~8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks

    Also known as: SAL-0951 group

06

What researchers measure

Primary outcomes

  1. Mean Hb level and 95% CI during the evaluation period after the 24-week treatment period or at the end of treatment

    (Hb levels during the evaluation period are defined as the mean value of Hb levels at Weeks 20, 22, and 24 \[or end-of-treatment date\])

    Time frame: at Weeks 20, 22, and 24 [or end-of-treatment date]

07

Study locations

1 site
  • The First Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong 510062, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2002 to primary completion in Oct 2024, 271 months.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 271 months is above that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2024
First posted
Dec 6, 2024
StartActual
Feb 22, 2002
Primary completionActual
Oct 18, 2024
CompletionActual
Oct 28, 2024
Last update
Dec 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06720233
Responsible party
Sponsor
First posted
Dec 6, 2024
Start date
Feb 22, 2002
Primary completion
Oct 18, 2024
Completion
Oct 28, 2024
Last update
Dec 6, 2024

Study contacts

Wei Chen, Ph.D
principal investigator · First Affiliated Hospital, Sun Yat-Sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SAL-0951

Start the discussion